Hologic (NASDAQ:HOLX) PT Lowered to $76.00 at Evercore ISI

Hologic (NASDAQ:HOLX) had its price target trimmed by Evercore ISI from $78.00 to $76.00 in a report published on Tuesday, Benzinga reports. The brokerage currently has an in-line rating on the medical equipment provider’s stock.

Several other brokerages also recently commented on HOLX. Citigroup raised Hologic from a neutral rating to a buy rating and upped their price objective for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. StockNews.com raised shares of Hologic from a hold rating to a buy rating in a research report on Friday, May 3rd. Argus boosted their price target on Hologic from $89.00 to $95.00 and gave the company a buy rating in a report on Thursday, May 9th. Needham & Company LLC restated a buy rating and set a $90.00 price objective on shares of Hologic in a report on Friday, May 3rd. Finally, JPMorgan Chase & Co. lifted their price objective on Hologic from $85.00 to $91.00 and gave the company an overweight rating in a report on Friday, May 3rd. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $85.55.

Hologic Stock Performance

Hologic stock opened at $73.48 on Tuesday. The company’s 50-day moving average price is $74.10 and its 200-day moving average price is $74.35. The company has a quick ratio of 3.29, a current ratio of 3.97 and a debt-to-equity ratio of 0.52. The company has a market cap of $17.15 billion, a PE ratio of 37.49, a price-to-earnings-growth ratio of 2.45 and a beta of 0.99. Hologic has a twelve month low of $64.02 and a twelve month high of $82.45.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.05. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company’s revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.06 EPS. On average, equities research analysts forecast that Hologic will post 4.08 EPS for the current fiscal year.

Institutional Trading of Hologic

Several large investors have recently added to or reduced their stakes in HOLX. Norges Bank purchased a new stake in shares of Hologic in the 4th quarter valued at $217,529,000. Pinebridge Investments L.P. grew its holdings in Hologic by 39.8% during the fourth quarter. Pinebridge Investments L.P. now owns 397,251 shares of the medical equipment provider’s stock worth $28,384,000 after acquiring an additional 113,050 shares during the period. Louisiana State Employees Retirement System purchased a new position in Hologic during the fourth quarter valued at approximately $1,057,000. Thematics Asset Management increased its holdings in shares of Hologic by 18.0% during the 4th quarter. Thematics Asset Management now owns 433,487 shares of the medical equipment provider’s stock valued at $30,973,000 after purchasing an additional 66,158 shares in the last quarter. Finally, Cibc World Markets Corp boosted its holdings in Hologic by 133.2% during the fourth quarter. Cibc World Markets Corp now owns 31,524 shares of the medical equipment provider’s stock worth $2,252,000 after buying an additional 18,005 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.